Zeaxanthin dipalmitate alleviates hepatic injury induced by superimposed chronic hepatitis B and non-alcoholic steatohepatitis in non-obese mice.
Study Goal
The researchers aimed to evaluate the therapeutic effects and safety of zeaxanthin dipalmitate (ZD) in alleviating hepatic injury induced by HBV and NASH in non-obese mice.
Results Summary
ZD coadministration showed evident therapeutic effects by alleviating pathological events in HBV transgenic mice with NASH. Long-term ZD treatment was found to be safe.
Population
HBV transgenic mice with non-obese non-alcoholic steatohepatitis (NASH).
Effective Dosage
2 mg/kg, three times per week.
Duration
8 weeks.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
methionine choline-deficient (MCD) diet | increase | typical non-obese non-alcoholic steatohepatitis (NASH) and HBV symptoms | wild-type and HBV transgenic mice | - | gained | #1 |
gavage of 2 mg/kg zeaxanthin dipalmitate (ZD) three times per week | decrease | pathological events | HBV transgenic mice model | - | exhibited evident therapeutic effects | #2 |
long-term vehicle-ZD treatment | no change | - | - | - | was found to be safe | #3 |
ZD | decrease | hepatic injury induced by superimposed HBV and NASH | non-obese mice | - | is a promising and safe hepato-protective agent | #4 |
A hepatitis B virus (HBV) transgenic mice model was used to establish the fatty liver superimposed model by feeding the methionine choline-deficient (MCD) diet for 8 weeks, with or without the gavage of 2 mg/kg zeaxanthin dipalmitate (ZD) three times per week. Both wild-type and HBV transgenic mice, with MCD diet, gained typical non-obese non-alcoholic steatohepatitis (NASH) and HBV symptoms. Coadministration with ZD exhibited evident therapeutic effects through alleviating those pathological events. Moreover, long-term vehicle-ZD treatment was found to be safe. Thus, ZD is a promising and safe hepato-protective agent against hepatic injury induced by superimposed HBV and NASH in non-obese mice.